Obigen Pharma Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-325.96	-274.31	-245.29	-218.21
Depreciation & Amortization	113.96	111.3	106.55	100.82
Other Amortization	0.73	0.74	-	-
Stock-Based Compensation	13.01	17.24	40.11	10.98
Other Operating Activities	0.08	1.03	0.39	0.04
Change in Accounts Receivable	0.36	-0.53	-0.83	-0.01
Change in Accounts Payable	-5.37	11.41	4.31	0.98
Change in Other Net Operating Assets	-40.07	-9.01	-7.68	-11.93
Operating Cash Flow	-243.26	-142.13	-102.44	-117.32
Capital Expenditures	-5.71	-26.63	-25.15	-161.37
Sale (Purchase) of Intangibles	-	-1.49	-	-
Investment in Securities	181.7	127.6	-739.3	-
Other Investing Activities	0.04	-0.02	-2.27	-2.4
Investing Cash Flow	176.02	99.46	-766.72	-163.77
Long-Term Debt Repaid	-14.8	-13.01	-6.73	-6.62
Net Debt Issued (Repaid)	-14.8	-13.01	-6.73	-6.62
Issuance of Common Stock	20.55	-	652.48	307.53
Other Financing Activities	-	-0	0.55	0
Financing Cash Flow	5.75	-13.01	646.3	300.9
Net Cash Flow	-61.49	-55.68	-222.87	19.81
Free Cash Flow	-248.98	-168.76	-127.59	-278.7
Free Cash Flow Per Share	-2.34	-1.59	-1.25	-3.67
Cash Interest Paid	1.72	2.77	0.85	0.96
Levered Free Cash Flow	-136.91	-75.23	-47.8	-
Unlevered Free Cash Flow	-135.83	-73.98	-46.79	-
Change in Working Capital	-45.08	1.88	-4.19	-10.95

Source: S&P Global Market Intelligence. Standard template. Financial Sources.